CSTONE PHARMA-B (02616) rose more than 9% again. At the time of writing, the stock was up 9.18% to HK$7.02, with a turnover of HK$70.8136 million. On the news front, according to the semi-annual review adjustments of the FTSE Global Equity Index Series (FTSE GEIS) released by the global authoritative index compiler FTSE Russell, CSTONE PHARMA-B has been successfully included as a constituent of the FTSE China Small Cap Index. The relevant adjustments will officially take effect after the market close on March 20, 2026. Guoyuan International noted that the company's PD-1/VEGF/CTLA-4 trispecific antibody demonstrates excellent safety and efficacy data. A global multi-center Phase II clinical study is currently underway, with 200 patients already enrolled. As clinical data begins to be released progressively starting in March this year, a significant business development deal is anticipated.